(Public, NASDAQ:CRME)   Watch this stock  
Find more results for CRME
+0.01 (0.35%)
Oct 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.80 - 2.94
52 week 2.73 - 9.21
Open 2.90
Vol / Avg. 115,508.00/61,247.00
Mkt cap 57.60M
P/E     -
Div/yield     -
EPS -1.11
Shares 20.38M
Beta 0.90
Inst. own 229%
Nov 11, 2016
Q3 2016 Cardiome Pharma Corp Earnings Release (Estimated) Add to calendar
Sep 13, 2016
Cardiome Pharma Corp at Rodman & Renshaw Global Investment Conference
Aug 11, 2016
Cardiome Pharma Corp at Canaccord Genuity Growth Conference
Aug 9, 2016
Q2 2016 Cardiome Pharma Corp Earnings Call
Aug 9, 2016
Q2 2016 Cardiome Pharma Corp Earnings Call
Aug 9, 2016
Q2 2016 Cardiome Pharma Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -127.12% -116.99%
Operating margin -99.86% -105.60%
EBITD margin - -95.19%
Return on average assets -59.48% -49.75%
Return on average equity -186.84% -131.96%
Employees 85 -
CDP Score - -


1441 Creekside Dr 6th Floor
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company's segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome. Cardiome also commercializes ESMOCARD and ESMOCARD LYO (esmolol hydrochloride), a short-acting beta-blocker used to control heart rate in various cardiovascular indications, in select European markets. Cardiome has also licensed TREVYENT, a development-stage drug device combination product that is under development for pulmonary arterial hypertension, in certain regions outside the United States.

Officers and directors

W. James O'Shea Chairman of the Board
Bio & Compensation  - Reuters
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Jennifer Archibald Chief Financial Officer
Bio & Compensation  - Reuters
Sheila M. Grant Chief Operating Officer
Bio & Compensation  - Reuters
David D. McMasters J.D. General Counsel
Bio & Compensation  - Reuters
Richard M. Glickman LL.D. Lead Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark H. N. Corrigan M.D. Director
Age: 58
Bio & Compensation  - Reuters
Robert James Meyer M.D. Director
Bio & Compensation  - Reuters
Arthur H. Willms Director
Age: 73
Bio & Compensation  - Reuters
Peter W Roberts CPA Independent Director
Bio & Compensation  - Reuters